Catabasis Names Ex-Alkermes Exec Komjathy Chief Commercial Officer

Andrew Komjathy has been appointed chief commercial officer of Catabasis Pharmaceuticals (NASDAQ: [[ticker:CATB]]). He joins the Cambridge, MA, drug developer from Alkermes (NASDAQ: [[ticker:ALKS]]), where he was vice president of commercial sales. His experience also includes positions at Genzyme, Shire, and Biogen (NASDAQ: [[ticker:BIIB]]). Catabasis has changed its therapeutic focus several times

, having pursued drugs for diabetes and high cholesterol among other diseases. Its most advanced compound, edasalonexent, is in Phase 3 testing in Duchenne muscular dystrophy.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan